p63 Protein expression in high risk diffuse large B-cell lymphoma

Journal of Clinical Pathology

Volumn 62, Issue 1, 2009, Pages 77-79

  Hallack Neto, A E ^a,b   Siqueira, S A C ^a   Dulley, F L ^a   Ruiz, M A ^a   Chamone, D A F ^a   Pereira, J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 6; PROTEIN P63;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GERMINAL CENTER; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; DNA-BINDING PROTEINS; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM STAGING; NEPRILYSIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 58349103112     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.059519     Document Type: Article

References (16)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profile. Nature 2000;3:503-11.
3. Chang CC, McClintock S, Cleveland RP, et al. Imunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-70.
4. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-13.
5. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial, and epithelial development. Nature 1999;398:714-8.
6. Fukushima N, Satoh T, Sueoka N, et al. Clinic-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Scl 2006;97:1050-5.
7. Di Como CJ, Urist MJ, Babayan I, et al. p63 Expression profiles in human normal and tumor tissues. Clin Cancer Res 2002;8:494-501.
8. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-27.
9. Hedvat CV, Teruya-Feldstein J, Puig P, et al. Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 2005;13:237-42.
10. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
11. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
12. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
13. Yang A, McKeon F. P63 and P53: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1:199-207.
14. Urist MJ, Di Como CJ, Lu ML, et al. Loss of p63 expression is associated with a tumor progression in bladder cancer. Am J Pathol 2002;161:1199-206.
15. Yamaguchi H, Inokuchi K, Sakuma Y. Mutation of p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 2001;15:1729-34.
16. Park CK, Oh YH. Expression of p63 in reactive hyperplasias and malignant lymphomas. J Korean Med Sci 2005;20:752-8.